Recruitment unclearEUCTR 2020-006062-36

A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesSchizophrenia

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Czechia · Estonia and 7 more locations
Compensation: Payment and expense reimbursement have not been verified.

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Recruitment unclear
Enrollment listed in the registry: 260
Sponsor: Newron Pharmaceuticals S.p.A.
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2, Phase 3
Locations: Czechia, Estonia, Germany, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2020-006062-36
Official title: Show the full official title
A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 M...

Need help understanding this study?

Leave your email and we’ll get in touch to discuss your questions and possible next steps.

Recruitment & locations

Status unknown

Czechia · Estonia · Germany

6 more locations

Hungary
Italy
Latvia
Poland
Romania
Spain

Registry details

Historical country statuses

Czechia — Completed
Germany — Completed
Estonia — Completed
Spain — Ongoing
Hungary — Completed
Italy — Completed
Latvia — Prematurely Ended
Poland — Completed
Romania — Ongoing

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Newron Pharmaceuticals S.p.A.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me